Quantcast


Last updated: September 06. 2013 7:40PM - 772 Views
Associated Press



Story Tools:

Font Size:

Social Media:

(AP) Federal regulators have approved Celgene Inc.'s drug Abraxane to treat late-stage pancreatic cancer.


In experimental trials, the drug extended the lives of patients by a little less than two months more than those treated with the current standard drug.


Abraxane is already approved to treat breast cancer and a type of lung cancer. It accounted for $155 million in revenue for Celgene in the second quarter.


Pancreatic cancer is considered especially deadly and hard to treat. It typically causes few symptoms until it has spread enough that it can't be surgically removed.


The National Cancer Institute estimates about 45,000 patients will be diagnosed and about 38,000 will die from the disease this year.


Associated Press
Comments
All user comments are subject to our Terms of Service. Users may flag inappropriate comments.
comments powered by Disqus



Featured Businesses


Poll



Info Minute



Gas Prices

Wilkes-Barre Gas Prices provided by GasBuddy.com